Rethinking phase 2 trials in amyotrophic lateral sclerosis.

Although edaravone, in a small phase 2 study, showed highly significant reductions in CSF 3-nitrotyrosine, a marker of oxidative stress, 35 these results were not reported in the later studies that led to licensing.

also in 132,142 other papers